
Please try another search
By Dhirendra Tripathi
Investing.com – Johnson & Johnson (NYSE:JNJ) stock was up 1.2% in Wednesday’s premarket trading as the company raised its full-year guidance for sales and earnings after a robust second quarter.
The company benefited a little from its COVID-19 vaccine and much more from its medical devices business, which boomed as hospitals resumed the medical procedures they had delayed during the pandemic.
The company’s consumer health business grew 10%, pharmaceutical operations 14% while medical devices rose 59%.
The company expects full-year sales of $93.8 billion to $94.6 billion including $2.5 billion-contribution from its COVID-19 vaccine. Discounting the COVID-19 jab, it still translates into growth of 10.5%-11.5%.
Overall annual adjusted diluted earnings per share are seen at $9.60-$9.70.
Second-quarter adjusted diluted EPS came at $2.48 on sales of $23.31 billion. Both numbers were higher than the estimated $2.29 and $22.5 billion, respectively.
The company’s forecast of $2.5 billion in revenue from sales of COVID-19 vaccines is in stark contrast to Pfizer 's (NYSE:PFE) estimation of $26 billion and Moderna 's (NASDAQ:MRNA) $19.2 billion.
Both companies have said they expect to profit from their vaccines, while J&J has said it will make its shots available on a not-for-profit basis during the pandemic, according to Reuters.
By David Ljunggren and Steve Scherer OTTAWA (Reuters) -Canada on Thursday said it plans to ban the use of China's Huawei Technologies Co Ltd and ZTE Corp (HK:0763) 5G gear to...
By Manas Mishra and Michael Erman (Reuters) - An advisory panel to the U.S. Centers for Disease Control and Prevention (CDC) on Thursday voted to recommend COVID-19 vaccine...
By Davit Kirakosyan VF Corp. (NYSE:VFC) shares rose more than 3% after-hours following the company’s reported Q4 results, which came in worse than the Street expectations, while...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.